FLASCO

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

bayer health
  • FLASCO
  • March 20, 2018

The NCCN guidelines were updated. CRC now includes the new dose escalation for Stivarga as a result of the ReDos study.  Read more at OncLive.com here http://www.onclive.com/web-exclusives/nccn-recommends-regorafenib-dose-escalation-in-metastatic-crc.

Who’s Online

There are no users currently online